Clinical relevance of the ESKAPE pathogens

By J. Pendleton, S. Gorman, B. Gilmore. Expert Review of Anti-Infective Therapy, 2013

1,317 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Emerging Strategies to Combat ESKAPE Pathogens in the Era of Antimicrobial Resistance: A Review (2019, background): “5% Hospital Acquired Infection (HAIs) in the world (Rice, 2008; Allegranzi et al., 2011; Ibrahim et al., 2012; Pendleton et al., 2013).”
A deep learning genome-mining strategy for biosynthetic gene cluster prediction (2019, background): “The global rise in antibiotic resistance (3,4), the increased promise of immunomodulatory agents in cancer treatment (5), and the continued need for development of new drugs across novel and complex biology is contingent upon the identification of structurally diverse bioactive compounds (6–8).”
Antibiotic resistance and persistence—Implications for human health and treatment perspectives (2020, neutral): “Due to this ability to rapidly develop resistances, many Enterobacter spp. strains are only susceptible to a few last-resort antibiotics such as colistin and tigecycline (Pendleton et al , 2013).”
Phage Therapy in the Postantibiotic Era (2019, background): “activity of antibiotics through multiple resistance mechanisms (25).”